

LARGEST BIOTECH EMPLOYERS 1-10

THE LIST

Ranked by N.E. employees, ties ranked by total employees

RANK	COMPANY	NEW ENGLAND EMPLOYEES	TOTAL EMPLOYEES	MAIN FOCUS	2008 REVENUE MARKET CAPITAL	CEO TITLE
1	Genzyme Corp. Cambridge www.genzyme.com	4,600	11,000	Biotechnology	\$4.6B DNR	Henri Termeer Chairman/CEO
2	Biogen Idec Cambridge www.biogenidec.com	1,900	4,700	Biotechnology	\$4.1B DNR	James C. Mullen President/CEO/Director
3	IDEXX Laboratories Inc. Westbrook, ME www.idexx.com	1,761	4,800	Diagnostics for veterinary health care industry	\$1B \$3B	Jonathan W. Ayers Chairman/President/CEO
4	Millipore Corp. Billerica www.millipore.com	1,693	5,867	Life science tools	\$1.6B \$3.9B	Martin D. Madaus Chairman/President/CEO
5	Charles River Laboratories Wilmington www.criver.com	1,300	8,500	Contract Research	DNR DNR	Jim Foster CEO
6	PAREXEL International Waltham www.parexel.com	1,200	9,130	Biopharmaceutical services	\$1.05B \$745,000,000	Josef H. von Rickenbach Chairman/CEO
7	The Jackson Laboratory Bar Harbor, ME www.jax.org	1,177	1,297	Genetics	\$166M (operating rev.) NA	Rick Woychik President/CEO
8	Vertex Pharmaceuticals Inc. Cambridge www.vrtx.com	1,100	1,400	Pharmaceuticals, Biotechnology	\$175.5M \$869M	Matthew Emmens Chairman/President/CEO
9	Shire Human Genetic Therapies (HGT) Cambridge www.shire.com	975	975	Biopharmaceuticals	\$482M \$10.7B	Sylvie Gregoire President Shire HGT
10	Millennium: The Takeda Oncology Co. Cambridge www.millennium.com	950	1,250	Pharmaceuticals	DNR DNR	Deborah Dunsire President/CEO

SOURCE: MHT SURVEYS

COMPANIES THAT DID NOT RESPOND TO SURVEY REQUESTS ARE NOT INCLUDED ON THIS LIST.

Workforce for largest employers dropped 16% year over year

Manufacturing problems at Genzyme Corp., ranked No. 1 on Mass High Tech's list of New England's largest biotech employers, may turn out to be a blessing in disguise, according to one industry analyst.

Simos Simeonidis, senior biotechnology analyst at Rodman & Renshaw LLC in New York, said the Cambridge-based biotech is likely past the worst of its problems with contaminants in its manufacturing facilities that began in the summer. Being forced to solve the problems should lead to a better 2010 for the

company, Simeonidis said.

"(The problems) have to be addressed because the market responded negatively," he said.

Nationally, Simeonidis said the sector is performing well, despite some money being taken out of it when Roche Holding AG's acquisition of Genentech Inc. closed in March. Treatments for rare diseases and cancer treatments will continue to be major focuses for local and national biotech companies, Simeonidis said. Treatments for lupus, cystic fibrosis, hepatitis C and rheumatoid arthritis should also continue to attract investment in 2010.


When it comes to jobs, the number of people employed in New England by the 20 largest biotech

dropped more than 16 percent, from 23,973 in 2008 to 20,084 this year, according to MHT research.

The local biotech sector should be safe from large-scale layoffs after a number of small companies shed workers in late 2008 and the first half of 2009, which included the news that CombinatoRx Inc. cut its staff by half a year ago or that Synta Pharmaceuticals Corp. laid off 90 in March. As a result, the job market should be flush with talent for other biotech to absorb, Simeonidis said.

"I think things have stabilized in Boston and the rest of the country," he said. **MHT**

BRENDAN LYNCH | BLYNCH@MASSHIGHTECH.COM



Problem Solved.

When it comes to intellectual property disputes, our trial attorneys offer the right combination. We know business. We know science and technology. We deliver solutions.

IP LITIGATION, PATENTS, TRADEMARKS, TRANSACTIONS, COPYRIGHTS

**HAMILTON
BROOK SMITH
REYNOLDS**
Intellectual Property Law

Massachusetts In, Texas Out – Bay State primed as ideal patent suit venue. Learn more at www.hbsr.com.

Ranked by N.E. employees, ties ranked by total employees

RANK	COMPANY	NEW ENGLAND EMPLOYEES	TOTAL EMPLOYEES	MAIN FOCUS	2008 REVENUE MARKET CAPITAL	CEO TITLE
11	Sepracor Inc. Marlborough www.sepracor.com	900	2,100	Pharmaceuticals	\$1.3B \$1.7B	Adrian Adams President/CEO
12	EMD Serono Inc. Rockland www.emdserono.com	835	1,000	Biopharmaceuticals	\$6.8B DNR	Fereydown Firouz President/CEO
13	Cubist Pharmaceuticals Inc. Lexington www.cubist.com	353	581	Pharmaceuticals	\$433.6M \$1B	Michael W. Bonney President/CEO
14	Alkermes Inc. Cambridge www.alkermes.com	279	DNR	Biotechnology	\$327M \$816.9M	Richard Pops Chairman/President/CEO
15	ImmunoGen Inc. Waltham www.immunogen.com	212	212	Biotechnology	\$40.3M \$450M	Daniel M. Junius President/CEO
16	Infinity Pharmaceuticals Cambridge www.infi.com	180	180	Pharmaceuticals	DNR \$160M	Steven Holtzman Chairman/CEO
17	Alnylam Pharmaceuticals Cambridge www.alnylam.com	179	179	Biotechnology	DNR \$907.1M	John Maraganore, Ph.D. CEO
18	Momenta Pharmaceuticals Inc. Cambridge www.momentapharma.com	175	175	Biotechnology	DNR \$374M	Craig Wheeler CEO
19	Ironwood Pharmaceuticals Cambridge www.ironwoodpharma.com	165	165	Pharmaceuticals	DNR DNR	Peter Hecht CEO
20	ATMI Life Sciences Danbury, CT www.atmi.com	150	750	Biopharmaceuticals	\$339M \$500M	Doug Neugold CEO

SOURCE: MHT SURVEYS

COMPANIES THAT DID NOT RESPOND TO SURVEY REQUESTS ARE NOT INCLUDED ON THIS LIST.

Advance Your Career in Science & Technology

UMass Lowell's College of Engineering Graduate Programs in Engineering

UMass Lowell has earned a distinguished reputation nationally & internationally for its engineering programs in:

- Biomedical Engineering & Biotechnology
- Biotechnology & Bioprocessing*
- Chemical Engineering
- Civil & Environmental Engineering
- Computer Engineering
- Electrical Engineering
- Energy Engineering
- Environmental Studies
- Mechanical Engineering
- Medical Plastics*
- Plastics Engineering
- Renewable Energy Engineering*

*Graduate certificates.

UMass Lowell's College of Management The Business of Science and Technology in the 21st Century

NEW! Master of Science in Innovation & Technological Entrepreneurship (MSITE)

The Master of Science in Innovation & Technological Entrepreneurship (MSITE) enables engineers, business majors and scientists to drive innovation in today's global workforce. Graduates of the MSITE program are prepared to manage innovation in established firms or to launch new technology-oriented ventures.

Also available: Master's in Business Administration (MBA) – On Campus or Online!

UMass Lowell's College of Arts & Sciences Life Sciences & Biotech Programs

In addition to its programs in Arts, Humanities and Social Sciences, UMass Lowell's College of Arts & Sciences offers a wide array of graduate programs, including new professional masters degrees in the Sciences:

- Biological Sciences
- Chemistry
- Computer Science
- Environmental, Earth and Atmospheric Sciences
- Marine Sciences
- Mathematical Sciences
- Physics

UMass Lowell's Division of Continuing Studies Earn a Graduate Degree or Certificate Entirely ONLINE!

UMass Lowell offers a variety of graduate degrees and certificates available entirely ONLINE including:

- Online Graduate Certificate in Laboratory & Biological Safety
- Online Graduate Certificate in Clinical Pathology
- Online Master's Degree in Health Management & Policy*
- Online Graduate Certificates in Health Management, Policy & Informatics*
- Online Graduate Certificate in Plastics Engineering
- Online MBA
- Online Graduate Certificate in Foundations of Business

*Blended online/on campus program.

UMass Lowell is an Equal Opportunity/Affirmative Action, Title IX, H/V, ADA 1990 University.



CALL FOR MORE INFO
800-656-GRAD

VISIT US ONLINE AT
continuinged.uml.edu/LifeSciences
or www.uml.edu/grad

